Business context and reporting period
ImmuCell Corporation’s Form 10-K covers the fiscal year ended December 31, 2014. The company develops and sells animal-health products, primarily for dairy and beef markets. Its lead product, First Defense, prevents calf scours; Mast Out, a Nisin-based treatment for subclinical mastitis, remains in development and requires FDA approval.
Financial performance and position
| Metric | 2014 | 2013 |
|---|---|---|
| Product sales | $7.597 million | $6.007 million |
| Gross margin | $4.449 million; 59% of sales | $3.061 million; 51% of sales |
| Operating income (loss) | ($206,000) | ($20,000) |
| Net income (loss) | ($167,000); ($0.06) per share | $117,000; $0.04 per share |
| Cash from operating activities | $302,000 | $1.099 million |
| Capital expenditures | $1.536 million | $598,000 |
| Cash, cash equivalents and investments | $3.835 million | $5.255 million |
| Net working capital | $4.460 million | $6.632 million |
| Bank debt outstanding | $896,000 | $1.087 million |
First Defense and related extensions generated 91.6% of 2014 product sales. Total liabilities were $1.793 million and stockholders’ equity was $9.258 million at year-end. The company said available capital and product-sale gross margin should fund operations for at least the next 12 months; its $500,000 credit line was unused at year-end.
Material changes versus the prior period
- Sales increased 26%, with domestic sales up 27% and international sales up 23%. Fourth-quarter sales were $2.205 million, up 41% year over year; fourth-quarter net income was $131,000 versus a $151,000 loss.
- Gross margin improved to 59% from 51%. Management attributed the prior-year pressure partly to reduced production and equipment repairs; it cautioned that the unusually strong 61% gross margin in the second half of 2014 was not expected to be sustainable.
- Product-development expense rose 89% to $2.179 million, principally reflecting investment in Mast Out manufacturing and regulatory work. The company recorded a full-year net loss, despite returning to profitability in the second half.
- Cash and investments declined by $1.420 million, while operating cash flow fell from $1.099 million to $302,000. Capital spending increased substantially, and working capital decreased by $2.172 million.
Outlook, risks and unusual items
- Management expected First Defense sales growth and the second-half profitability trend to continue into 2015. It projected first-quarter 2015 First Defense sales approximately 62% above first-quarter 2014, but reported demand exceeded production capacity; management estimated at least $795,000 of unfilled First Defense orders at March 31, 2015. These are estimates, not formal full-year guidance.
- The company planned additional production investment, including up to approximately $1.640 million authorized for 2015 capital expenditures, chiefly to expand First Defense capacity. Equipment lead times meant the program might not be fully completed until the first quarter of 2016.
- Mast Out had completed FDA environmental-impact, target-animal-safety and effectiveness technical sections. Human-food-safety completion was anticipated by the end of 2015; the company targeted initial CMC submission in fourth-quarter 2015 and approval/test marketing around year-end 2016. Manufacturing issues with Norbrook could delay the timeline by at least a year. Expanded commercial-scale production would require additional funding; a plant had been estimated to cost approximately $13 million.
- Management attributed the 2014 loss in part to a non-recurring investment in Mast Out facilities and processing equipment. The company reported $973,000 of related expense and $1.492 million of capital expenditures during 2014. A prospective partner’s $250,000 option fee boosted 2013 results but did not recur.
- Key risks include reliance on First Defense and two distributors, which accounted for 61% of product sales and 71% of trade receivables in 2014; capacity constraints and potential lost sales; dependence on key suppliers and manufacturing facilities; regulatory approval and financing needs for Mast Out; and volatile dairy and beef economics. The filing reports no legal proceedings. The independent auditor issued an unqualified opinion on the financial statements; management assessed internal controls as effective, without an auditor attestation.
Important facts for investors to verify
- Whether production investments alleviate the First Defense backlog and translate into shipments, sales and cash generation.
- Whether the reported 59% annual gross margin is repeatable, given management’s warning about the second-half margin.
- Progress and costs for Mast Out’s FDA reviews, sterile-fill manufacturing arrangements and funding for commercial-scale production.
- Liquidity and cash use as capital expenditures and product-development spending continue; confirm debt maturities, covenant compliance and access to the credit line.
- Ongoing customer concentration, receivable collection and the financial condition of major distributors.